ここから本文です。

Update:March 29, 2017

Director's remarks

Japanese

Preface

Hiroki Nagase

Chiba Cancer Center Research Institute (CCCRI)
Hiroki Nagase, M.D., Ph.D. (Director)

  Both Chiba Cancer Center (CCC) and Chiba Cancer Center Research Institute (CCCRI) were established in 1972. Overcoming the superb achievement of the last 44 years, CCCRI is moving forward with new endeavor to create innovative research for cancer patients, together with the comprehensive Cancer Center of CCC, which embodied in both Cancer Center Hospital and Cancer Center Research Institute. We strive to eradicate cancer from Chiba citizen’s lives by creating new knowledge and integrating a breakthrough research with excellence in education. We focus on generating a personalized medicine for cancer patients and community care with mind-body support, through our incessant research efforts.

 In addition to the local government support, CCCRI constantly received millions dollars support from external agents including Ministry of Education, Culture, Sports, Science and Technology (MEXT), Ministry of Health, Labour and Welfare (MHLW), National Institute of Biomedical Innovation (NIBIO) and recently Japan Agency for Medical Research and Development (AMED). This means CCCRI will retain its status conducting outstanding researches as the third domestic public comprehensive cancer center established in Japan.

 CCCRI has grown to become one of the world’s foremost cancer research organizations. CCCRI has a distinguished record of achievement and recognition in understanding the genetic basis of childhood cancer and our scientists continue to make significant progress in this area of research. CCCRI has a uniquely dedicated focus on translational science and clinical opportunities, developing molecularly targeted therapies. For instance, a mutual collaboration among CCCRI, Chiba University, Nihon University and Kyoto University has developed a platform of candidate therapeutic molecules targeting genetic and epigenetic mutations in cancer. CCCRI collaborating with The University of Tokyo and Saitama Cancer Center has developed a unique next generation “OMICS” approach to identify new drug target for childhood cancers. CCCRI has also made a significant effort for cancer biobank, cancer epidemiology and population-based cancer registry in Chiba prefecture of the total population: over 6 millions. These efforts should provide high quality translational and/or epidemiological researches, together with a large amount of hospital/ population based big data and the outstanding basic researches.

 We have been taking steps forward in facilitating cancer research discoveries that will lead to improvements in prevention, diagnosis and treatment for cancer patients. And it is likely to prosper accordingly!

Hiroki Nagase